INFLUENCE OF DRY EYE DISEASE (DED) TREATMENT WITH LIPIFLOW® ON CORNEAL TOPOGRAPHIC AND ABERROMETRY MEASUREMENTS
Published 2022 - 26th ESCRS Winter Meeting
Reference: FP87 | Type: Abstracts | DOI: 10.82333/xee6-sm60
Authors: Peter Pego* 1 , Filomena Ribeiro 2
1Vision Center - Ophthalmology Department,Hospital da Luz,Lisboa,Portugal;Medical School,University of Lisbon,Lisbon,Portugal;Institute for Environmental Health,University of Lisbon,Lisbon,Portugal, 2Vision Center - Ophthalmology Department,Hospital da Luz,Lisboa,Portugal;Medical School,University of Lisbon,Lisbon,Portugal;Visual Sciences Research Center,University of Lisbon,Lisbon,Portugal
Purpose
To evaluate the influence of Dry Eye Disease (DED) treatment with LipiFlow® on corneal topographic and aberrometry measurements.
Setting
Single center prospective study.
Methods
20 eyes of 10 patients with DED were analyzed. Before and 1 month after DED treatment with LipiFlow® patients were asked to complete the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire. All patients were evaluated for breakup time test (BUT) and corneal topographic and aberrometry measurements with Cassini® topographer, Orbscan® II topographer and Zywave® II wavefront aberrometer, before and 1 month after DES treatment with Lipiflow®. Given most variables were non-normally distributed, the non-parametric Wilcoxon test was used to compare pre- vs post-treatment assessments. Statistical significance was set at p<0.05.
Results
When comparing pre- vs post-treatment assessments, DED symptoms (lower SPEED score; n=20, 12.6 vs 5.7, p<0.001) and signs (higher BUT; n=20, 4.35 vs 9.05, p<0.001) improved one month after LipiFlow® treatment. On the other hand, 5mm zone astigmatism power at Orbscan® II increased after treatment (n=20, 1.21 vs 1.37, p=0.023) and Cassini® Surface Indices high order aberrations HOA (n=16, 1.09 vs 0.49, p=0.002) and surface asymmetry index SAI (n=16, 1.39 vs 0.59, p=0.002) decreased after treatment. None of the other analyzed variables showed statistically significant differences from pre- to post-treatment.
Conclusion
LipiFlow® seems to be effective in DED treatment with improvement in both symptoms and signs. DED treatment seems to influence the accurate acquisition of topographic and aberrometry parameters, particularly in the measurement of astigmatism and improving Surface Indices, such as HOA and SAI. The acquisition of accurate corneal topographic and aberrometry values is essential in both refractive surgery and cataract surgery. These results highlight the role that DED treatment can play in obtaining more accurate ocular surface values.